Article
EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.
The New England journal of medicine - 28 Oct 2010
Choi Young Lim, Soda Manabu, Yamashita Yoshihiro, Ueno Toshihide, Takashima Junpei, Nakajima Takahiro, Yatabe Yasushi, Takeuchi Kengo, Hamada Toru, Haruta Hidenori, Ishikawa Yuichi, Kimura Hideki, Mitsudomi Tetsuya, Tanio Yoshiro, Mano Hiroyuki
Abstract excerpt
The EML4 (echinoderm microtubule-associated protein-like 4)-ALK (anaplastic lymphoma kinase) fusion-type tyrosine kinase is an oncoprotein found in 4 to 5% of non-small-cell lung cancers, and clinical trials of specific inhibitors of ALK for the treatment of such tumors are currently under way. Here, we report the discovery of two secondary mutations within the kinase domain of EML4-ALK in tumor cells isolated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.